The modulation of estrogen-induced apoptosis as an interpretation of the women’s health initiative trials

References

• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trail. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmeno-pausal women with hysterectomy: extended follow-up of the women’s health initiative randomized placebo-controlled trail. Lancet Oncol. 2012;13:476–486.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol. 2015;3:296–305.
   Google Scholar
• Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293:1164–1167.
   PubMed Web of Science ®Google Scholar
• Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167–1170.
   PubMed Web of Science ®Google Scholar
• Boyd S. On oophorectomy in cancer of the breast. Bmj. 1900;ii:1161–1167.
   Google Scholar
• Lathrop AE, Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J Cancer Res. 1916;1:1–19.
   PubMedGoogle Scholar
• Lacassagne A. A comparative study of the carcinogenic action of certain oestrogenic hormones. Am J Cancer. 1936;28:735–740.
   Google Scholar
• Haddow A, Watkinson JM, Paterson E, et al. Influence of synthetic oestrogens on advanced malignant disease. Br Med J. 1944;2:393–398.
   PubMedGoogle Scholar
• Haddow A. David A. Karnofsky Memorial Lecture. Thoughts on chemical therapy. Cancer. 1970;26:737–754.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72:7–25.
   PubMed Web of Science ®Google Scholar
• Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6:2028–2036.
   PubMed Web of Science ®Google Scholar
• Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer–survival or death? J Clin Oncol. 2008;26:3073–3082.
   PubMed Web of Science ®Google Scholar
• Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2015;22:R1–31.
   PubMed Web of Science ®Google Scholar
• Song RX, Mor G, Naftolin F, et al. Effect of long term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001;93:1714–1723.
   PubMedGoogle Scholar
• Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97:1746–1759.
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Cunliffe HE, Lewis-Wambi JS, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011;108:18879–18886.
   PubMed Web of Science ®Google Scholar
• Fan P, Cunliffe HE, Maximov PY, et al. Integration of downstream signals of insulin-like growth factor-1 receptor by endoplasmic reticulum stress for estrogen-induced growth or apoptosis in breast cancer cells. Mol Cancer Res. 2015;13:1367–1376.
   Web of Science ®Google Scholar
• Jordan VC. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst. 2014;106:pii: dju296.
   Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–816.
   PubMed Web of Science ®Google Scholar
• Lønning PE, Taylor PD, Anker G, et al. High dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67: 111–116.
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009;302:774–780.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Avoiding the bad and enhancing the good of soy supplements in breast cancer. J Natl Cancer Inst. 2014;106: pii: dju233.
   Google Scholar
• Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103:296–305.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study. Am J Epidemiol. 2008;167:1407–1415.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008;167:1207–1216.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chlebowski RT, Anderson GL, et al. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res. 2014;16:R30.
   PubMed Web of Science ®Google Scholar
• He XY, Liao YD, Yu S, et al. Sex hormone binding globulin and risk of breast cancer in postmenopausal women: a meta-analysis of prospective studies. Horm Metab Res. 2015;47:485–490.
   PubMed Web of Science ®Google Scholar
• Joshi P, Goodwin P, Khokha R. Progestrone exposure and breast cancer risk. JAMA Oncol. 2015;1:3.
   Google Scholar
• Jordan VC, Maximov PY, Fan P. Progesterone and synthetic progestin controversies. JAMA Oncology. 2015;1:7.
   Google Scholar
• Obiorah IE, Fan P, Jordan VC. Breast cancer cell apoptosis with phytoestrogens is dependent on an estrogen-deprived state. Cancer Prev Res. 2014;7:939–949.
   PubMed Web of Science ®Google Scholar
• Courtin A, Communal L, Vilasco M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. 2012;131:49–63.
   PubMed Web of Science ®Google Scholar
• Sweeney EE, Fan P, Jordan VC. Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women’s health initiative study. Cancer Res. 2014;74:7060–7068.
   PubMed Web of Science ®Google Scholar
• Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptive to stimulate human breast cancer cell proliferation. Cancer Res. 1992;52:6539–6546.
   PubMed Web of Science ®Google Scholar